Otsuka: The Nursing-Home Sales Force Behind the Abilify Settlement

Otsuka American Pharmaceutical Inc. agreed to pay over $4 million to settle the Otsuka Abilify nursing homes fraud case, which alleged off-label promotion for pediatric use and dementia-related psychosis. The government alleged that its representatives participated in a specialized sales force calling almost exclusively on nursing homes. The government said the potential dementia market drove the pitch.

The Department of Justice announced the resolution on March 27, 2008. A physician brought the underlying False Claims Act qui tam case. It reached into the manufacturer side of nursing-home drug marketing, where the decision about which patients to pursue begins before a prescription reaches the pharmacy.

Who Ran the Abilify Sales Teams?

Otsuka developed Abilify in Japan and entered an agreement with Bristol-Myers Squibb to co-promote the drug in the United States. Under that agreement, Otsuka representatives worked on sales teams led primarily by Bristol-Myers Squibb managers.

The settling company was Otsuka American Pharmaceutical, the American subsidiary of Otsuka Pharmaceutical Co., Ltd.

That division of responsibility matters to someone who worked on the sales team. The representative’s employer, the manager directing the work and the company making the drug can occupy different places in the same campaign.

How Abilify Reached Nursing Homes

The government alleged that Otsuka representatives participated in a specialized long-term-care sales force whose calls went almost exclusively to nursing homes. According to the Justice Department, dementia-related psychosis was far more prevalent there than schizophrenia or bipolar disorder. The government alleged that the sales force promoted Abilify for dementia-related psychosis because of the potential market benefit.

The sales territory is the revealing part. A force aimed almost entirely at nursing homes was reaching a patient population with a different mix of conditions from the adult schizophrenia and bipolar uses the Food and Drug Administration had approved. The government’s allegation connected the choice of customers to the use being promoted.

For a sales representative or manager, that connection lives in familiar work: territory assignments, call plans, promotional instructions and the accounts the team was expected to develop. Those are the records we would examine alongside the prescribing that followed. The sales organization helps explain why a particular drug reached a particular facility.

Abilify Promotion Reached the Patients the Black Box Warned About

The government alleged that Otsuka knowingly promoted Abilify for pediatric use and dementia-related psychosis from 2002 through the end of 2005. It said Otsuka participated in directing sales representatives to call on child psychiatrists and other pediatric specialists and urge them to prescribe the drug to children.

During the conduct period, Abilify lacked FDA approval for treating children. By the settlement announcement, the agency had approved specified adolescent schizophrenia and pediatric bipolar uses.

For elderly patients with dementia-related psychosis, the announcement said the FDA had not determined Abilify safe and effective and had required a black-box warning on its packaging concerning that use. The alleged pitch put sales growth ahead of the residents the warning was meant to protect.

The Otsuka Settlement and Whistleblower Reward

Otsuka’s settlement allocated approximately $2.3 million to the federal government and $1.7 million to participating states’ Medicaid programs.

Bristol-Myers Squibb had agreed to pay more than $515 million in September 2007 in a broader settlement covering Abilify promotion, provider payments and drug pricing. Otsuka’s later agreement resolved the remaining allegations in the same whistleblower action.

Otsuka also entered a Corporate Integrity Agreement with the Department of Health and Human Services Office of Inspector General as part of the settlement.

The physician who brought the case was allocated a reward from the federal settlement and an additional share of the state settlement. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

What Evidence Is Needed to Prove Fraud?

For a drug-promotion case, we connect the commercial instructions to the prescription, the patient’s clinical record and the government-paid claim. The Otsuka allegations show why evidence inside the business can begin with the sales organization.

A co-promotion agreement and management records can identify who directed the campaign. Sales assignments, call records and payroll or travel records can connect those instructions to the representatives visiting facilities. Medication orders, clinical notes and pharmacy billing records can connect the pitch to the resident and the payment. We work through those connections with the people who know what the records meant in daily practice.

Commercial influence can also reach the prescription through a pharmacy. In a separate case involving Omnicare, the government alleged that Amgen benefits, including rebates, grants, speaker payments and data fees, were tied to switching Medicaid beneficiaries to Aranesp. The Omnicare resolution shows another place to find the commercial decision behind a drug recommendation: the pharmacy’s arrangement with the manufacturer.

The Diagnosis Can Serve a Commercial Purpose Too

Nursing homes used inappropriate schizophrenia diagnoses to justify antipsychotics and inflate nursing-home star ratings, according to a March 2026 report. The HHS inspector general reviewed 40 nursing-home inspections by the Centers for Medicare & Medicaid Services and found instances in which medical directors made inappropriate diagnoses to justify prescribing the drugs.

The report described how excluding residents diagnosed with schizophrenia from the antipsychotic measure created that incentive. A diagnosis changed how the prescribing appeared in the rating. For nursing-home healthcare staff, the clinical notes behind that diagnosis can be as revealing as the manufacturer’s sales instructions.

The inspector general also described concern about drugs used as chemical restraints to control residents’ behavior, and the increased risk of death these drugs pose for elderly patients with dementia. A medication order, the diagnosis supporting it and the sales message encouraging it can tell different stories about whose needs the prescription served. Our work is to connect those decisions to the public money that paid for the drug.

You Know What Drove the Prescribing

If your work involves nursing-home diagnoses, pharmacy recommendations, drug promotion or the health care claims that followed, speak to one of our whistleblower experts about what drove the prescribing. We build the case with you and bring in pharmaceutical fraud whistleblower lawyers who understand manufacturer promotion and nursing-home pharmacy claims. We stay beside you as your knowledge of the business becomes the foundation of your strongest whistleblower case.